Put @VivekSubbiah's #ESMO26 lecture on drugging the undruggables on your list. The pearl for fellows: KRAS G12C went from undruggable to approved by trapping the inactive GDP-bound

MeDucation· @MeDucationai · X·2026-10-22 00:50· 4 days agoScore45

Body · original

Put @VivekSubbiah's #ESMO26 lecture on drugging the undruggables on your list. The pearl for fellows: KRAS G12C went from undruggable to approved by trapping the inactive GDP-bound state, and the next wave is going after the active RAS(ON) state instead.

584 views · 4 likes · 1 repost · 0 replies

Conference abstracts

1039PNCT05067283 NCT05067283 NCT05067283matched by Developmental therapeutics

Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study

https://esmocongress.esmo.org

2551TIPNCT07541170 NCT07541170 NCT07541170matched by NSCLC, early stage

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

2683Pmatched by NSCLC, metastatic

First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01

https://esmocongress.esmo.org

引用@

📍Don’t miss the lecture @myESMO #ESMO26 “Drugging the undruggables: The next wave of targeted therapies” @OncoAlert @oncodaily Link - https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/177

在 X 查看被引用的帖子

Source: MeDucation · x.com